Patents by Inventor Sha-Sha Wang
Sha-Sha Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240060132Abstract: Methods for predicting the development of sepsis in a subject at risk for developing sepsis are provided. In one method, features in a biomarker profile of the subject are evaluated. The subject is likely to develop sepsis if these features satisfy a particular value set. Methods for predicting the development of a stage of sepsis in a subject at risk for developing a stage of sepsis are provided. In one method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to have the stage of sepsis if these feature values satisfy a particular value set. Methods of diagnosing sepsis in a subject are provided. In one such method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to develop sepsis when the plurality of features satisfies a particular value set.Type: ApplicationFiled: February 13, 2023Publication date: February 22, 2024Inventors: James A. Garrett, Sha-Sha Wang, Keith Thornton, Richard L. Moore, William Keating, William A. Nussbaumer, Craig C. Whiteford
-
Patent number: 11578367Abstract: Methods for predicting the development of sepsis in a subject at risk for developing sepsis are provided. In one method, features in a biomarker profile of the subject are evaluated. The subject is likely to develop sepsis if these features satisfy a particular value set. Methods for predicting the development of a stage of sepsis in a subject at risk for developing a stage of sepsis are provided. In one method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to have the stage of sepsis if these feature values satisfy a particular value set. Methods of diagnosing sepsis in a subject are provided. In one such method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to develop sepsis when the plurality of features satisfies a particular value set.Type: GrantFiled: October 8, 2019Date of Patent: February 14, 2023Assignee: Becton, Dickinson and CompanyInventors: James A. Garrett, Sha-Sha Wang, Keith Thornton, Richard L. Moore, William Keating, William A. Nussbaumer, Craig C. Whiteford
-
Publication number: 20220372554Abstract: A direct chemical lysis composition includes an assay compatible buffer composition and an assay compatible surfactant. When combined with a specimen storage composition, such compositions prevent undesired modifications to nucleic acid and proteins lysed from cells in the biological sample. Assays of samples from such compositions do not require expensive and time-consuming steps such as centrifugation and prolonged high temperature processing. The direct chemical lysis composition of the present invention permits direct nucleic acid extraction from the cells in the biological sample without the need to decant off the transport media or otherwise exchange the transport media with assay compatible buffers. There is no need to combine the sample with proteinase K or another enzyme to extract nucleic acids from the cells. A method for lysing cells to obtain target nucleic acid for assay and a kit for combining the direct chemical lysis composition with a sample are also contemplated.Type: ApplicationFiled: August 8, 2022Publication date: November 24, 2022Inventors: Feng Yang, Sha-Sha Wang, Laurence Michael Vaughan, Michael Porter, Elaine Rose
-
Patent number: 11434519Abstract: A direct chemical lysis composition includes an assay compatible buffer composition and an assay compatible surfactant. When combined with a specimen storage composition, such compositions prevent undesired modifications to nucleic acid and proteins lysed from cells in the biological sample. Assays of samples from such compositions do not require expensive and time-consuming steps such as centrifugation and prolonged high temperature processing. The direct chemical lysis composition of the present invention permits direct nucleic acid extraction from the cells in the biological sample without the need to decant off the transport media or otherwise exchange the transport media with assay compatible buffers. There is no need to combine the sample with proteinase K or another enzyme to extract nucleic acids from the cells. A method for lysing cells to obtain target nucleic acid for assay and a kit for combining the direct chemical lysis composition with a sample are also contemplated.Type: GrantFiled: April 30, 2019Date of Patent: September 6, 2022Assignee: Becton, Dickinson and CompanyInventors: Feng Yang, Sha-Sha Wang, Laurence Michael Vaughan, Michael Porter, Elaine Rose
-
Publication number: 20210087632Abstract: Methods for predicting the development of sepsis in a subject at risk for developing sepsis are provided. In one method, features in a biomarker profile of the subject are evaluated. The subject is likely to develop sepsis if these features satisfy a particular value set. Methods for predicting the development of a stage of sepsis in a subject at risk for developing a stage of sepsis are provided. In one method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to have the stage of sepsis if these feature values satisfy a particular value set. Methods of diagnosing sepsis in a subject are provided. In one such method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to develop sepsis when the plurality of features satisfies a particular value set.Type: ApplicationFiled: October 8, 2019Publication date: March 25, 2021Inventors: James A. Garrett, Sha-Sha Wang, Keith Thornton, Richard L. Moore, William Keating, William A. Nussbaumer, Craig C. Whiteford
-
Patent number: 10443099Abstract: Methods for predicting the development of sepsis in a subject at risk for developing sepsis are provided. In one method, features in a biomarker profile of the subject are evaluated. The subject is likely to develop sepsis if these features satisfy a particular value set. Methods for predicting the development of a stage of sepsis in a subject at risk for developing a stage of sepsis are provided. In one method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to have the stage of sepsis if these feature values satisfy a particular value set. Methods of diagnosing sepsis in a subject are provided. In one such method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to develop sepsis when the plurality of features satisfies a particular value set.Type: GrantFiled: September 10, 2015Date of Patent: October 15, 2019Assignee: Becton, Dickinson and CompanyInventors: James A. Garrett, Sha-Sha Wang, Keith Thornton, Richard L. Moore, William Keating, William A. Nussbaumer, Craig C. Whiteford
-
Publication number: 20190256893Abstract: A direct chemical lysis composition includes an assay compatible buffer composition and an assay compatible surfactant. When combined with a specimen storage composition, such compositions prevent undesired modifications to nucleic acid and proteins lysed from cells in the biological sample. Assays of samples from such compositions do not require expensive and time-consuming steps such as centrifugation and prolonged high temperature processing. The direct chemical lysis composition of the present invention permits direct nucleic acid extraction from the cells in the biological sample without the need to decant off the transport media or otherwise exchange the transport media with assay compatible buffers. There is no need to combine the sample with proteinase K or another enzyme to extract nucleic acids from the cells. A method for lysing cells to obtain target nucleic acid for assay and a kit for combining the direct chemical lysis composition with a sample are also contemplated.Type: ApplicationFiled: April 30, 2019Publication date: August 22, 2019Inventors: Feng Yang, Sha-Sha Wang, Laurence Michael Vaughan, Michael Porter, Elaine Rose
-
Patent number: 10323267Abstract: A direct chemical lysis composition includes an assay compatible buffer composition and an assay compatible surfactant. When combined with a specimen storage composition, such compositions prevent undesired modifications to nucleic acid and proteins lysed from cells in the biological sample. Assays of samples from such compositions do not require expensive and time-consuming steps such as centrifugation and prolonged high temperature processing. The direct chemical lysis composition of the present invention permits direct nucleic acid extraction from the cells in the biological sample without the need to decant off the transport media or otherwise exchange the transport media with assay compatible buffers. There is no need to combine the sample with proteinase K or another enzyme to extract nucleic acids from the cells. A method for lysing cells to obtain target nucleic acid for assay and a kit for combining the direct chemical lysis composition with a sample are also contemplated.Type: GrantFiled: March 11, 2016Date of Patent: June 18, 2019Assignee: Becton Dickinson and CompanyInventors: Feng Yang, Sha-Sha Wang, Laurence Michael Vaughan, Michael Porter, Elaine Rose
-
Patent number: 10190152Abstract: A direct chemical lysis composition includes an assay compatible buffer composition and an assay compatible surfactant. When combined with a specimen storage composition, such compositions prevent undesired modifications to nucleic acid and proteins lysed from cells in the biological sample. Assays of samples from such compositions do not require expensive and time-consuming steps such as centrifugation and prolonged high temperature processing. The direct chemical lysis composition of the present invention permits direct nucleic acid extraction from the cells in the biological sample without the need to decant off the transport media or otherwise exchange the transport media with assay compatible buffers. There is no need to combine the sample with proteinase K or another enzyme to extract nucleic acids from the cells. A method for lysing cells to obtain target nucleic acid for assay and a kit for combining the direct chemical lysis composition with a sample are also contemplated.Type: GrantFiled: September 2, 2010Date of Patent: January 29, 2019Assignee: Becton, Dickinson and CompanyInventors: Feng Yang, Sha-Sha Wang, Laurence Michael Vaughan, Michael Porter, Elaine Rose
-
Patent number: 9499858Abstract: A high-sensitivity, low-background immuno-amplification assay is provided, which offers a streamlined workflow suitable for high-throughput assays of clinically relevant samples, such as blood and other bodily fluids. The assay comprises the use of two proximity members that each comprise an analyte-specific binding component conjugated to an oligonucleotide. Binding an analyte brings the oligonucleotide moieties of the proximity members in sufficiently close contact that the oligonucleotides form an amplicon. The presence of the analyte then is detected through amplification of the amplicon and detection of the amplified nucleic acids. The sensitivity of the assay of the present invention is improved by preventing spurious or non-specific amplicon formation by proximity members that are not complexed with an analyte.Type: GrantFiled: January 11, 2013Date of Patent: November 22, 2016Assignee: Becton, Dickinson and CompanyInventors: James G. Nadeau, Tobin Hellyer, Dolores M. Berger, William Nussbaumer, Robert Rosenstein, Andrew Kuhn, Sha-Sha Wang, Keith Edward Thornton
-
Publication number: 20160194687Abstract: A direct chemical lysis composition includes an assay compatible buffer composition and an assay compatible surfactant. When combined with a specimen storage composition, such compositions prevent undesired modifications to nucleic acid and proteins lysed from cells in the biological sample. Assays of samples from such compositions do not require expensive and time-consuming steps such as centrifugation and prolonged high temperature processing. The direct chemical lysis composition of the present invention permits direct nucleic acid extraction from the cells in the biological sample without the need to decant off the transport media or otherwise exchange the transport media with assay compatible buffers. There is no need to combine the sample with proteinase K or another enzyme to extract nucleic acids from the cells. A method for lysing cells to obtain target nucleic acid for assay and a kit for combining the direct chemical lysis composition with a sample are also contemplated.Type: ApplicationFiled: March 11, 2016Publication date: July 7, 2016Applicant: Becton, Dickinson and CompanyInventors: Feng Yang, Sha-Sha Wang, Laurence Michael Vaughan, Michael Porter, Elaine Rose
-
Publication number: 20160168638Abstract: Methods for predicting the development of sepsis in a subject at risk for developing sepsis are provided. In one method, features in a biomarker profile of the subject are evaluated. The subject is likely to develop sepsis if these features satisfy a particular value set. Methods for predicting the development of a stage of sepsis in a subject at risk for developing a stage of sepsis are provided. In one method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to have the stage of sepsis if these feature values satisfy a particular value set. Methods of diagnosing sepsis in a subject are provided. In one such method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to develop sepsis when the plurality of features satisfies a particular value set.Type: ApplicationFiled: September 10, 2015Publication date: June 16, 2016Inventors: James A. Garrett, Sha-Sha Wang, Keith Thornton, Richard L. Moore, William Keating, William A. Nussbaumer, Craig C. Whiteford
-
Publication number: 20150152473Abstract: A high-sensitivity, low-background immuno-amplification assay is provided, which offers a streamlined workflow suitable for high-throughput assays of clinically relevant samples, such as blood and other bodily fluids. The assay comprises the use of two proximity members that each comprise an analyte-specific binding component conjugated to an oligonucleotide. Binding an analyte brings the oligonucleotide moieties of the proximity members in sufficiently close contact that the oligonucleotides form an amplicon. The presence of the analyte then is detected through amplification of the amplicon and detection of the amplified nucleic acids. The sensitivity of the assay of the present invention is improved by preventing spurious or non-specific amplicon formation by proximity members that are not complexed with an analyte.Type: ApplicationFiled: January 11, 2013Publication date: June 4, 2015Applicant: BECTON, DICKINSON AND COMPANYInventors: James G. Nadeau, Tobin Hellyer, Dolores M. Berger, William Nussbaumer, Robert Rosenstein, Andrew Kuhn, Sha-Sha Wang, Keith Edward Thornton
-
Publication number: 20140141435Abstract: Methods for predicting the development of sepsis in a subject at risk for developing sepsis are provided. In one method, features in a biomarker profile of the subject are evaluated. The subject is likely to develop sepsis if these features satisfy a particular value set. Methods for predicting the development of a stage of sepsis in a subject at risk for developing a stage of sepsis are provided. In one method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to have the stage of sepsis if these feature values satisfy a particular value set. Methods of diagnosing sepsis in a subject are provided. In one such method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to develop sepsis when the plurality of features satisfies a particular value set.Type: ApplicationFiled: August 12, 2013Publication date: May 22, 2014Applicant: Beckton, Dickinson and CompanyInventors: James A. Garrett, Sha-Sha Wang, Keith Thornton, Richard L. Moore, William Keating, William A. Nussbaumer, Craig C. Whiteford
-
Patent number: 8372605Abstract: A high-sensitivity, low-background immuno-amplification assay is provided, which offers a streamlined workflow suitable for high-throughput assays of clinically relevant samples, such as blood and other bodily fluids. The assay comprises the use of two proximity members that each comprise an analyte-specific binding component conjugated to an oligonucleotide. Binding an analyte brings the oligonucleotide moieties of the proximity members in sufficiently close contact that the oligonucleotides form an amplicon. The presence of the analyte then is detected through amplification of the amplicon and detection of the amplified nucleic acids. The sensitivity of the assay of the present invention is improved by preventing spurious or non-specific amplicon formation by proximity members that are not complexed with an analyte.Type: GrantFiled: March 25, 2011Date of Patent: February 12, 2013Assignee: Becton, Dickinson and CompanyInventors: James Nadeau, Tobin J. Hellyer, Dolores M. Berger, William Nussbaumer, Robert Rosenstein, Andrew Kuhn, Sha-Sha Wang, Keith Edward Thornton
-
Patent number: 8323929Abstract: The invention employs an unlabeled signal primer comprising a 5? adapter sequence for detection of variations in nucleic acid target sequences. The detection system further comprises a reporter probe, the 3? end of which hybridizes to the complement of the 5? adapter sequence of the signal primer to produce a 5? overhang. Polymerase is used to fill in the overhang and synthesize the complement of the 5? overhang of the reporter probe. Synthesis of the reporter probe complement is detected, either directly or indirectly, as an indication of the presence of the target.Type: GrantFiled: April 7, 2009Date of Patent: December 4, 2012Assignee: Becton, Dickinson and CompanyInventors: Sha-Sha Wang, Keith Thornton, James G. Nadeau, Tobin J. Hellyer
-
Publication number: 20110244457Abstract: A high-sensitivity, low-background immuno-amplification assay is provided, which offers a streamlined workflow suitable for high-throughput assays of clinically relevant samples, such as blood and other bodily fluids. The assay comprises the use of two proximity members that each comprise an analyte-specific binding component conjugated to an oligonucleotide. Binding an analyte brings the oligonucleotide moieties of the proximity members in sufficiently close contact that the oligonucleotides form an amplicon. The presence of the analyte then is detected through amplification of the amplicon and detection of the amplified nucleic acids. The sensitivity of the assay of the present invention is improved by preventing spurious or non-specific amplicon formation by proximity members that are not complexed with an analyte.Type: ApplicationFiled: March 25, 2011Publication date: October 6, 2011Applicant: Becton, Dickinson and CompanyInventors: James Nadeau, Tobin Hellyer, Dolores M. Berger, William Nussbaumer, Robert Rosenstein, Andrew Kuhn, Sha Sha Wang, Keith Thornton
-
Publication number: 20110105350Abstract: Methods for predicting the development of sepsis in a subject at risk for developing sepsis are provided. In one method, features in a biomarker profile of the subject are evaluated. The subject is likely to develop sepsis if these features satisfy a particular value set. Methods for predicting the development of a stage of sepsis in a subject at risk for developing a stage of sepsis are provided. In one method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to have the stage of sepsis if these feature values satisfy a particular value set. Methods of diagnosing sepsis in a subject are provided. In one such method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to develop sepsis when the plurality of features satisfies a particular value set.Type: ApplicationFiled: May 7, 2010Publication date: May 5, 2011Inventors: James A. Garrett, Sha-Sha Wang, Keith Thornton, Richard L. Moore, William Keating, William A. Nussbaumer, Craig C. Whiteford
-
Patent number: 7932060Abstract: A high-sensitivity, low-background immuno-amplification assay is provided, which offers a streamlined workflow suitable for high-throughput assays of clinically relevant samples, such as blood and other bodily fluids. The assay comprises the use of two proximity members that each comprise an analyte-specific binding component conjugated to an oligonucleotide. Binding an analyte brings the oligonucleotide moieties of the proximity members in sufficiently close contact that the oligonucleotides form an amplicon. The presence of the analyte then is detected through amplification of the amplicon and detection of the amplified nucleic acids. The sensitivity of the assay of the present invention is improved by preventing spurious or non-specific amplicon formation by proximity members that are not complexed with an analyte.Type: GrantFiled: April 19, 2004Date of Patent: April 26, 2011Assignee: Becton, Dickinson and CompanyInventors: James Nadeau, Tobin Hellyer, Dolores Berger, William Nussbaumer, Robert Rosenstein, Andrew Kuhn, Sha Sha Wang, Keith Thornton
-
Publication number: 20110059455Abstract: A direct chemical lysis composition includes an assay compatible buffer composition and an assay compatible surfactant. When combined with a specimen storage composition, such compositions prevent undesired modifications to nucleic acid and proteins lysed from cells in the biological sample. Assays of samples from such compositions do not require expensive and time-consuming steps such as centrifugation and prolonged high temperature processing. The direct chemical lysis composition of the present invention permits direct nucleic acid extraction from the cells in the biological sample without the need to decant off the transport media or otherwise exchange the transport media with assay compatible buffers. There is no need to combine the sample with proteinase K or another enzyme to extract nucleic acids from the cells. A method for lysing cells to obtain target nucleic acid for assay and a kit for combining the direct chemical lysis composition with a sample are also contemplated.Type: ApplicationFiled: September 2, 2010Publication date: March 10, 2011Applicant: BECTON, DICKINSON AND COMPANYInventors: Feng Yang, Sha-Sha Wang, Laurence Michael Vaughan, Michael Porter, Elaine Rose